The present disclosure is directed to certain inhibitors of kinases such as ITK, BLK, BMX, BTK, JAK3, TEC, TXK, HER2 (ERBB2), or HER4 (ERBB4), in particular ITK, pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by such kinases.
本公开涉及针对ITK、BLK、B
MX、
BTK、JAK3、
TEC、TXK、
HER2(ER
BB2)或
HER4(ER
BB4)等激酶的某些
抑制剂,特别是ITK,包含这些化合物的制药组合物以及治疗由这些激酶介导的疾病的方法。